On Friday, BMO Capital Markets adjusted its outlook on Regeneron (NASDAQ:REGN) Pharmaceuticals, lowering the price target to $1,190 from the previous $1,300 while maintaining an Outperform rating on the stock. The revision follows Regeneron's recent financial results and market developments related to its ophthalmology products.
The firm's decision comes in the wake of Regeneron's earnings report, which despite showing a top and bottom-line beat, revealed concerns over the performance of its Eylea High-Dose (HD) product.
The analyst cited the competitive pressures expected from Amgen (NASDAQ:AMGN)'s biosimilar entry and the upcoming prefilled syringe formulation of Vabsymo as reasons for the revised estimates for Regeneron's ophthalmology business through 2024 and into early 2025.
Regeneron's management addressed these challenges during their earnings call, emphasizing the unique value proposition of their offerings. They pointed out the loyalty of Eylea patients and projected a potential boost in HD revenues in the second half of 2025 following the launch of the prefilled syringe.
The price target adjustment reflects a more cautious stance on the near-term prospects for Regeneron's ophthalmology franchise. The analyst noted significant reductions in the 2024 and 2025 franchise estimates, which informed the new target price for the NASDAQ:REGN shares.
Despite the near-term headwinds, the Outperform rating indicates that BMO Capital Markets still sees a positive long-term trajectory for Regeneron, factoring in the company's strategic responses and product pipeline. Management's confidence in the stickiness of Eylea's patient base and the anticipated revenue acceleration post-prefilled syringe introduction contribute to this outlook.
In other recent news, Regeneron Pharmaceuticals reported an 11% increase in total revenues for the third quarter, reaching $3.72 billion, largely driven by Dupixent's global sales. Despite facing pricing pressures, the company ended the quarter with a strong financial position, holding $15.6 billion in cash and marketable securities.
Several analyst firms have adjusted their price targets for Regeneron. Piper Sandler cut its target to $1,195 from $1,242, citing slower-than-expected adoption of the Eylea HD treatment. Leerink Partners reduced its target to $880 from $1,077, reflecting recalibrated earnings expectations for the coming years. Evercore ISI made a slight adjustment from $1,175 to $1,170, noting significant market pressures faced by the company.
Regeneron is currently developing around 40 clinical programs and has a genetics database of over 2.5 million sequenced exomes. The company expects interim results from a Phase II lung cancer study and pivotal data for itepekimab in COPD by 2025.
InvestingPro Insights
Recent market data from InvestingPro provides additional context to BMO Capital Markets' analysis of Regeneron Pharmaceuticals. The company's stock has experienced significant short-term pressure, with a 10.16% decline over the past week and a 19.94% drop in the last month. This aligns with BMO's more cautious stance on the company's near-term prospects.
Despite these challenges, InvestingPro Tips highlight Regeneron's financial strength. The company operates with a moderate level of debt, and its cash flows can sufficiently cover interest payments. Additionally, Regeneron's liquid assets exceed short-term obligations, suggesting a solid financial foundation as it navigates competitive pressures in its ophthalmology business.
InvestingPro data shows Regeneron's P/E ratio at 22.83, indicating that investors are still willing to pay a premium for the company's earnings despite recent setbacks. The company's revenue growth of 6.46% over the last twelve months and a strong operating income margin of 30.14% underscore its continued profitability, supporting BMO's maintained Outperform rating.
For investors seeking a more comprehensive analysis, InvestingPro offers 14 additional tips for Regeneron Pharmaceuticals, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.